{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:42:28Z","timestamp":1790422948637,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background and Purpose:<\/jats:title>\n            <jats:p>Stroke is a major cause of chronic neurological disability. There is considerable interest in understanding how acute transcriptome changes evolve into subacute and chronic patterns that facilitate or limit spontaneous recovery. Here we mapped longitudinal changes in gene expression at multiple time points after stroke in mice out to 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n              Adult C57BL\/6 mice were subjected to transient middle cerebral artery occlusion. Longitudinal transcriptome levels were measured at 10 time points after stroke from acute to recovery phases of ischemic stroke. Localization and the number of mononuclear phagocytes were determined in the postischemic brain. Whole-mount brain imaging was performed in asplenic mice receiving GFP\n              <jats:sup>+<\/jats:sup>\n              (green fluorescent protein)-tagged splenocytes.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sustained stroke-induced mRNA abundance changes were observed in both hemispheres with 2989 ipsilateral and 822 contralateral genes significantly perturbed. In the hemisphere ipsilateral to the infarct, genes associated with immune functions were strongly affected, including temporally overlapping innate and adaptive immunity and macrophage M1 and M2 phenotype-related genes. The strong immune gene activation was accompanied by the sustained infiltration of peripheral immune cells at acute, subacute, and recovery stages of stroke. The infiltrated immune cells were found in the infarcted area but also in remote regions at 2 months after stroke.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The study identifies that immune components are the predominant molecular signatures and they may propagate or continuously respond to brain injury in the subacute to chronic phase after central nervous system injury. The study suggests a potential immune-based strategy to modify injury progression and tissue remodeling in ischemic stroke, even months after the initiating event.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/strokeaha.120.029440","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T09:00:28Z","timestamp":1594285228000},"page":"2514-2525","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Sustained Increases in Immune Transcripts and Immune Cell Trafficking During the Recovery of Experimental Brain Ischemia"],"prefix":"10.1161","volume":"51","author":[{"given":"Wen","family":"Fury","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Tarrytown, NY (W.F., Y.B., L.E.M., S.D.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Woo","family":"Park","sequence":"additional","affiliation":[{"name":"Burke Neurological Institute, White Plains, NY (K.W.P., E.K., M.-s.W., S.C.)."},{"name":"Feil Brain Mind Research Institute, Weill Cornell Medicine, New York, NY (K.W.P., S.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhao","family":"Wu","sequence":"additional","affiliation":[{"name":"Departments of Cell, Developmental and Regenerative Biology (Z.W.), Icahn School of Medicine at Mount Sinai, New York, NY."},{"name":"Neuroscience (Z.W.), Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee","family":"Kim","sequence":"additional","affiliation":[{"name":"Burke Neurological Institute, White Plains, NY (K.W.P., E.K., M.-s.W., S.C.)."},{"name":"Vivian L. Smith Department of Neurosurgery at University of Texas Health Science Center at Houston (E.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-sook","family":"Woo","sequence":"additional","affiliation":[{"name":"Burke Neurological Institute, White Plains, NY (K.W.P., E.K., M.-s.W., S.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Tarrytown, NY (W.F., Y.B., L.E.M., S.D.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Tarrytown, NY (W.F., Y.B., L.E.M., S.D.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Croll","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Tarrytown, NY (W.F., Y.B., L.E.M., S.D.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-8227","authenticated-orcid":true,"given":"Sunghee","family":"Cho","sequence":"additional","affiliation":[{"name":"Burke Neurological Institute, White Plains, NY (K.W.P., E.K., M.-s.W., S.C.)."},{"name":"Feil Brain Mind Research Institute, Weill Cornell Medicine, New York, NY (K.W.P., S.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","article-title":"A systematic analysis for the global burden of disease study 2016.","volume":"18","author":"Collaborators GBDS. Global, Regional, and National Burden of Stroke, 1990-2016","year":"2019","unstructured":"Collaborators GBDS. Global, Regional, and National Burden of Stroke, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:439\u2013458.","journal-title":"Lancet Neurol"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30029-8"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2014.08.004"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f2b37f"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2011.45"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22497"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.11.090"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03508.x"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.01.004"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2674"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4146"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.020244"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11946-y"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-83"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4140-13.2014"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2699-18.2019"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/131.7.2067"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.659656"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2956"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.02.026"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2014.101"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1175202"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.08.010"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00081"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.57.8.1428","article-title":"Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial.","volume":"57","author":"Enlimomab Acute Stroke Trial I","year":"2001","unstructured":"Enlimomab Acute Stroke Trial I. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology. 2001;57:1428\u20131434.","journal-title":"Neurology"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086660"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0750-0"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4317-15.2016"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009426"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.750018"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.4.571"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000381105"},{"key":"e_1_3_5_34_2","first-page":"289","article-title":"[Secondary degeneration of the substantia nigra after cerebral infarctions including the striatum].","volume":"65","author":"Ohe Y","year":"2013","unstructured":"Ohe, Y, Hayashi, T, Uchino, A, Tanahashi, N. [Secondary degeneration of the substantia nigra after cerebral infarctions including the striatum]. Brain Nerve. 2013;65:289\u2013295.","journal-title":"Brain Nerve"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.204.3.9280270"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.23.3.328"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222878110"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1401965111"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.004075"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005640"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1523-19.2019"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2017.08.011"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0982-08.2008"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23569"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.120.029440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T14:50:50Z","timestamp":1715611850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.120.029440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1161\/STROKEAHA.120.029440"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.120.029440","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"2020-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}